Company Overview

vTv Therapeutics Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on the discovery and development of orally administered small-molecule therapies for metabolic and inflammatory diseases. The company operates primarily within the biotechnology and pharmaceutical industries, with research efforts historically centered on diabetes, obesity, liver disease, and central nervous system disorders. Its core value proposition has been the development of orally delivered therapeutics intended to improve patient compliance and expand treatment accessibility compared with injectable alternatives.

The company’s principal development programs have included cadisegliatin (formerly TTP399), a liver-selective glucokinase activator for type 1 diabetes, and earlier-stage inflammatory and metabolic disease candidates. vTv Therapeutics traces its origins to TransTech Pharma, founded in the late 1990s, before later rebranding as vTv Therapeutics and becoming publicly traded on Nasdaq under the ticker VTVT. The company has historically positioned itself around proprietary drug discovery technologies and structure-based chemistry capabilities intended to accelerate small-molecule development.

Business Operations

vTv Therapeutics generates revenue primarily through collaboration agreements, licensing arrangements, research partnerships, and, to a lesser extent, grants and milestone payments, as the company has not commercialized a product based on publicly available filings. Operations are centered on clinical research and drug development activities, with expenditures concentrated in research and development. The company’s lead operational focus has been its cadisegliatin program, which has undergone clinical evaluation in type 1 diabetes as an adjunctive oral therapy designed to improve glycemic control while reducing hypoglycemia risk.

The company’s operations are primarily U.S.-based, with research and corporate activities historically conducted from facilities in North Carolina. vTv Therapeutics has entered into strategic collaborations with external pharmaceutical and investment partners to support clinical development and financing activities. Public filings have referenced relationships involving licensing rights and development support tied to specific drug candidates. The company also maintains intellectual property portfolios covering compound composition, therapeutic applications, and related discovery technologies.

Strategic Position & Investments

vTv Therapeutics has focused its strategic direction on advancing late-stage metabolic disease assets while seeking external capital and partnership opportunities to support clinical development. A major strategic emphasis has been the advancement of cadisegliatin for type 1 diabetes management, particularly as an oral adjunct therapy that could potentially differentiate itself from insulin-only treatment approaches. The company has also evaluated broader applications in metabolic disease and inflammation, though several historical pipeline programs have been reduced, discontinued, or deprioritized over time according to public disclosures.

The company has pursued financing and development support through equity investments, licensing transactions, and collaborative arrangements. Public disclosures have identified relationships with institutional healthcare investors and pharmaceutical development partners connected to specific clinical programs. vTv Therapeutics has also continued investing in proprietary small-molecule discovery capabilities and clinical-stage metabolic therapies, positioning itself within the broader biotechnology sector focused on chronic disease management and precision metabolic regulation.

Geographic Footprint

vTv Therapeutics is headquartered in High Point, North Carolina, and its operational footprint is primarily concentrated in the United States. Clinical trials and development activities have involved partnerships with research institutions, contract research organizations, and clinical investigators across multiple U.S. regions. The company’s scale remains significantly smaller than multinational pharmaceutical peers, and available public disclosures indicate that most operational infrastructure is domestically centered.

Although the company does not maintain a broad global commercial footprint, its clinical development efforts have had relevance to international pharmaceutical markets due to the global prevalence of diabetes and metabolic disease. The company’s intellectual property protections and development strategies have included international patent considerations and potential out-licensing opportunities in overseas markets. Data regarding large-scale international operational infrastructure is inconclusive based on available public sources.

Leadership & Governance

vTv Therapeutics was originally associated with the leadership and scientific development efforts of TransTech Pharma prior to its evolution into the current public biotechnology company. Governance is overseen by a board of directors and executive management team responsible for clinical strategy, financing, regulatory oversight, and investor relations. Leadership communications and public filings have emphasized disciplined capital allocation, clinical execution, and advancement of differentiated oral therapies targeting unmet medical needs in metabolic disease.

Key executives identified in recent public company disclosures include:

• Paul Sekhri – Chairman
• Rich Nelson – Interim President and Chief Executive Officer
• Mark Erion, Ph.D. – Chief Scientific Officer
• Julie Anne Smith – Vice President, Clinical Operations
• Stephen Holcombe – Former Chief Executive Officer

The company’s leadership philosophy has emphasized advancing targeted clinical programs through strategic partnerships and evidence-driven development while maintaining a focused biotechnology operating structure. Executive leadership has also highlighted the importance of regulatory engagement, capital efficiency, and differentiated therapeutic mechanisms in competitive metabolic disease markets.